Completed PHASE4 INTERVENTIONAL NCT00357045

Antidepressant Prophylaxis for Interferon-Induced Depression: Efficacy of Paroxetine

Antidepressant Prophylaxis for Interferon-Induced Depression: Efficacy of Paroxetine; THE HEPDEP II STUDY

Sponsor: GlaxoSmithKline

Interventions Paroxetine

Updated 4 times since 2017 Last updated: Jul 25, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Major Depression and is currently completed. GlaxoSmithKline leads this study, which shows 4 recorded versions since 2026 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2017 — Jan 2021 [monthly]

Completed PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
Portland VA Medical Center
Schering-Plough

Data source: Portland VA Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.